Literature DB >> 8831915

Lipids and atherogenesis in diabetes mellitus.

D J Betteridge1.   

Abstract

Premature cardiovascular disease is a major burden in diabetes. Increasing cholesterol is associated with increasing vascular risk in diabetes and the absolute excess risk attributable to cholesterol is higher in diabetes than in non-diabetics. Total cholesterol and low density lipoprotein (LDL) cholesterol correlated with arterial endothelial dysfunction as assessed by reduced flow-mediated brachial artery dilatation in insulin-dependent diabetic patients. In non-insulin dependent diabetic patients hypertriglyceridaemia is common and is associated with the accumulation of intermediate density lipoproteins, abnormal postprandial lipid metabolism and small dense LDL. No trials of lipid lowering therapy in the primary or secondary prevention of cardiovascular disease have been targeted specifically to the diabetic population; nevertheless, guidelines have been published for the treatment of dyslipidaemia in diabetic patients recognising the evidence of benefit in non-diabetics and the high intrinsic risk of the diabetic.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8831915     DOI: 10.1016/0021-9150(96)05856-x

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  3 in total

Review 1.  Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia.

Authors:  J C Adkins; D Faulds
Journal:  Drugs       Date:  1997-10       Impact factor: 9.546

2.  Association between lipid biomarkers and osteoporosis: a cross-sectional study.

Authors:  Bo Kan; Qianqian Zhao; Lijuan Wang; Shanshan Xue; Hanqing Cai; Shuman Yang
Journal:  BMC Musculoskelet Disord       Date:  2021-09-06       Impact factor: 2.362

Review 3.  Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia.

Authors:  Gillian M Keating; Douglas Ormrod
Journal:  Drugs       Date:  2002       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.